What is Clear Guide Medical?
Clear Guide Medical is a specialized medical technology firm focused on the intersection of augmented reality (AR) and interventional radiology. Its core product, SCENERGY, serves as a sophisticated navigation tool that enhances the precision of invasive procedures by overlaying digital guidance onto live MRI, CT, and ultrasound feeds. By reducing the cognitive load on practitioners and improving procedural accuracy, the company addresses a critical pain point in modern healthcare: the need for safer, more efficient, and highly reproducible surgical interventions. The firm's market position is defined by its commitment to bridging the gap between diagnostic imaging and real-time procedural execution, effectively setting a new standard for surgical confidence.
How much funding has Clear Guide Medical raised?
Clear Guide Medical has raised a total of $10.3M across 6 funding rounds:
Unspecified
$3.8M
Series A
$3M
Private Equity
$1.2M
Unspecified
$2M
Debt
$150K
Debt
$223K
Unspecified (2015): $3.8M with participation from National Institutes of Health
Series A (2016): $3M led by Wildermuth Advisory
Private Equity (2016): $1.2M, investors not publicly disclosed
Unspecified (2018): $2M featuring National Institutes of Health
Debt (2020): $150K backed by PPP
Debt (2021): $223K with participation from PPP
Key Investors in Clear Guide Medical
National Institutes of Health
The National Institutes of Health (NIH), founded in 1887 and based in Bethesda, Maryland, is an agency of the United States Department of Health and Human Services and is the primary agency of the United States government responsible for biomedical and health-related research.
Wildermuth Advisory
A strategic advisory and investment firm focused on supporting high-growth companies through critical scaling phases.
PPP
Public-Private Partnership
What's next for Clear Guide Medical?
With the recent infusion of $223K, Clear Guide Medical is expected to prioritize the expansion of its clinical footprint and the refinement of its AI-driven imaging algorithms. The strategic roadmap likely includes deepening integration with existing hospital infrastructure and pursuing broader regulatory clearances to support the adoption of SCENERGY in diverse clinical environments. As the company transitions into this next phase of growth, the focus will remain on demonstrating long-term value through improved patient safety metrics and reduced procedural complications. Investors and industry stakeholders will be monitoring the firm's ability to convert this capital into sustained market penetration and technological leadership in the competitive medical imaging landscape.
See full Clear Guide Medical company page
